Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy

2022-01-02
drdehghani

Back to cancers ↩

Clinical insights into nanomedicine and biosafety: advanced therapeutic approaches for common urological cancers

Investigating Post-treatment Breast Pain Severity in Breast Cancer Patients and Its Correlation with Serum Vitamin D and hs-CRP Levels

Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Concurrent Use of Crocin During Chemoradiation for Esophageal Squamous Cell Carcinoma

📑 DOI: https://doi.org/10.1080/07357907.2021.1992420

Abstract

Objective

To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.

Material and method

364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA.

Results

Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers.

Conclusion

The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.